Researchers at Stanford University have developed a urine cell-free RNA (cfRNA) test that identifies bladder cancer with 96% sensitivity, potentially offering a more precise alternative to traditional diagnostic methods. Published this month in Nature Medicine, the study demonstrates that the test can differentiate between patients who will respond to Bacillus Calmette-Guérin (BCG) immunotherapy and those who will not, while also detecting minimal residual disease after surgery.
High Sensitivity Compared to Standard Cytology
The new cfRNA test significantly outperformed existing diagnostic tools in a cohort of 93 patients with known bladder cancer, achieving 96% sensitivity compared with 34% for urine cytology, as reported by Medscape. Unlike DNA-based tests, which can struggle with the "field effect"—where normal bladder cells shed mutations that are not cancerous—the RNA-based approach identifies the specific genes currently being expressed by tumor cells. This allows for more accurate phenotyping of the cancer, helping clinicians distinguish between low- and high-grade tumors and assess recurrence risk.
Predicting BCG Treatment Response
In a secondary analysis of 36 patients with intermediate- or high-risk non-muscle invasive bladder cancer, the researchers found that the cfRNA test served as a reliable indicator of treatment success. Among those who underwent BCG therapy, the test accurately separated responders from nonresponders. The research team developed a biomarker that linked T-cell immune signals to positive BCG outcomes, while tumor cell proliferation signals were associated with nonresponders. According to senior author Max Diehn, MD, PhD, the test’s ability to detect residual disease could eventually reduce the frequency of invasive cystoscopies, which currently require patients to undergo anesthesia every three months.
While the results are promising, the research team emphasized that large-scale prospective studies are required before the test can move into routine clinical practice. Dan Theodorescu, MD, PhD, director of the Cancer Center at The University of Arizona, noted that the assay’s ability to measure biologically relevant processes—rather than just the presence of cells—is a significant advancement.
Frequently Asked Questions
How does this test differ from existing DNA-based liquid biopsies?
DNA-based tests often face challenges with the "field effect," where benign cells shed mutations that can lead to false positives. Because the cfRNA test analyzes RNA, it captures the active gene expression of cells, allowing it to differentiate more accurately between cancer and normal tissue.
Could this test replace the need for regular cystoscopy?
Researchers at Stanford are optimistic that the test could reduce the need for frequent cystoscopies, which are invasive procedures performed under anesthesia. However, the study remains a proof-of-concept, and further prospective clinical trials must establish its reliability before it can replace current standard-of-care surveillance.
What is the next step for this technology?
The research team is moving toward large-scale prospective validation. This phase will involve further comparisons with other diagnostic tools to confirm that the cfRNA test remains effective for both detecting cancer and monitoring how well treatments like BCG are working in diverse patient groups.
Keep reading